The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by GOODHUE, A.
* Articles by SMITH, N. B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by GOODHUE, A.
* Articles by SMITH, N. B.
Related Collections
* Amphetamines
Am J Psychiatry 157:1021-1022, June 2000
© 2000 American Psychiatric Association


Letter to the Editor

Exacerbation of Psychosis by Phenylpropanolamine

ANGELIQUE GOODHUE, M.D., ROXANNE L. BARTEL, M.D., and NANCY B. SMITH, PHARM.D.
Salt Lake City, Utah

We report the case of a patient initially treated for methamphetamine psychosis whose psychotic symptoms recurred while she was taking phenylpropanolamine.

Ms. A was a 31-year-old woman with a history of methamphamine abuse who was initially admitted to the inpatient psychiatry unit with a depressed mood, command hallucinations, and paranoid delusions. She had been using methamphetamine heavily up until 3 weeks before admission. Her depressive symptoms, including anhedonia, decreased energy, increased sleep, suicidal ideation, and tearfulness, worsened 2 months before admission. In addition, her psychotic symptoms had been present for many weeks but had been getting progressively more severe. In the hospital, treatment with paroxetine was initiated because it had reportedly been effective previously in spite of episodic methamphetamine use. Ms. A was also treated with perphenazine. Her depressive symptoms improved, and her psychotic symptoms disappeared over 3 weeks. At discharge, she was no longer psychotic.

Six months later Ms. A was readmitted to the inpatient psychiatry unit after a 2-week recurrence of command hallucinations and paranoia. The results of a urine drug screening test were negative for methamphetamine; there was no historical evidence of resumed use. Approximately 3 weeks before admission Ms. A was prescribed a combination of phenylpropanolamine, 75 mg, and guaifenesin, 400 mg, for congestion. She had also been taking cimetidine for 1 month for gastritis. In the hospital she continued to received paroxetine, perphenazine, and oral contraceptive pills, which she had been taking as an outpatient. The congestion medication and cimetidine were stopped. Within 3 days the voices and paranoia had disappeared, and she was discharged.

It is commonly accepted that methamphetamine use can cause psychosis. It has also been reported that chronic exposure to methamphetamine may alter the response to stimuli, resulting in a recurrence of psychotic symptoms in abstinent patients (1, 2). For example, there may be an increased sensitivity to psychosis after exposure to stimulant amines (3). To our knowledge, psychosis activated by phenlypropanolamine has not previously been documented. We report that phenylpropanolamine can cause a recurrence of psychotic symptoms that were initially precipitated by previous methamphetamine use. It is unclear whether the concurrent administration of cimetidine, an inhibitor of hepatic metabolism, elevated the patient’s serum phenylpropanolamine level, although she did not demonstrate peripheral signs of toxicity. Once treatment with cimetidine and phenylpropanolamine had been discontinued, her psychosis remitted. Caution must clearly be used in prescribing phenylpropanolamine to former methamphetamine users with histories of psychosis. It is possible that other stimulant decongestants may be hazardous in these patients as well.

REFERENCES

  1. Sato M, Numachi Y, Hamamura T: Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992; 18:115–122
  2. Sato M: A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann NY Acad Sci 1992; 28:160–170
  3. Angrist B, Rotrosen J, Kleinberg D, Merriam V, Gershon S: Domaminergic agonist properties of ephedrine: theoretical implications. Psychopharmacology 1977; 55:115–120[Medline]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by GOODHUE, A.
* Articles by SMITH, N. B.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by GOODHUE, A.
* Articles by SMITH, N. B.
Related Collections
* Amphetamines


Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org